CN110494434B - 吡唑并氯苯基化合物、其组合物及其使用方法 - Google Patents

吡唑并氯苯基化合物、其组合物及其使用方法 Download PDF

Info

Publication number
CN110494434B
CN110494434B CN201880017772.2A CN201880017772A CN110494434B CN 110494434 B CN110494434 B CN 110494434B CN 201880017772 A CN201880017772 A CN 201880017772A CN 110494434 B CN110494434 B CN 110494434B
Authority
CN
China
Prior art keywords
compound
group
alkyl
compounds
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201880017772.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110494434A (zh
Inventor
M·扎克
F·A·罗梅罗
P-W·源
E·J·哈南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN110494434A publication Critical patent/CN110494434A/zh
Application granted granted Critical
Publication of CN110494434B publication Critical patent/CN110494434B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201880017772.2A 2017-03-14 2018-03-13 吡唑并氯苯基化合物、其组合物及其使用方法 Expired - Fee Related CN110494434B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/076598 2017-03-14
CN2017076598 2017-03-14
PCT/EP2018/056129 WO2018166993A2 (en) 2017-03-14 2018-03-13 Pyrazolochlorophenyl compounds, compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
CN110494434A CN110494434A (zh) 2019-11-22
CN110494434B true CN110494434B (zh) 2022-05-24

Family

ID=61655767

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880017772.2A Expired - Fee Related CN110494434B (zh) 2017-03-14 2018-03-13 吡唑并氯苯基化合物、其组合物及其使用方法

Country Status (5)

Country Link
US (2) US20200002346A1 (enExample)
EP (1) EP3596072B1 (enExample)
JP (1) JP2020510061A (enExample)
CN (1) CN110494434B (enExample)
WO (1) WO2018166993A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7256757B2 (ja) 2017-05-22 2023-04-12 エフ． ホフマン－ラ ロシュ アーゲー 処置用化合物及び組成物、並びにその使用方法
JP7657740B2 (ja) 2019-06-18 2025-04-07 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｊａｋキナーゼのピラゾロピリミジンスルホン阻害剤およびその使用
CN114026096B (zh) 2019-06-18 2025-02-07 豪夫迈·罗氏有限公司 四唑取代的吡唑并嘧啶类jak激酶抑制剂及其用途
WO2022256358A1 (en) * 2021-06-03 2022-12-08 Genentech, Inc. Process for preparing medicaments

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH11508583A (ja) 1995-07-06 1999-07-27 ゼネカ・リミテッド ペプチド系のフィブロネクチン阻害薬
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
AU2002361992A1 (en) 2001-12-20 2003-07-09 Bayer Aktiengesellschaft 1,4-dihydro-1,4-diphenylpyridine derivatives
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
WO2006070202A1 (en) * 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives having kinase modulating activity
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
JP5474354B2 (ja) * 2005-12-30 2014-04-16 アステックス、セラピューティックス、リミテッド 医薬化合物
US8435970B2 (en) * 2006-06-29 2013-05-07 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
JP2009542608A (ja) * 2006-06-29 2009-12-03 アステックス・セラピューティクス・リミテッド 医薬組合せ剤
AU2009259853A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
BRPI0914404A2 (pt) * 2008-10-31 2019-03-06 Genentech Inc "compostos, composição farmacêutica e método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak quinase em um paciente"
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
CA2929316C (en) * 2013-11-08 2021-12-28 Takeda Pharmaceutical Company Limited Pyrazole for the treatment autoimmune disorders
HRP20210935T1 (hr) 2014-05-23 2021-08-06 F. Hoffmann - La Roche Ag Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak
WO2017140825A1 (en) 2016-02-18 2017-08-24 F. Hoffmann-La Roche Ag Therapeutic compounds, compositions and methods of use thereof

Also Published As

Publication number Publication date
WO2018166993A2 (en) 2018-09-20
JP2020510061A (ja) 2020-04-02
EP3596072A2 (en) 2020-01-22
US20200002346A1 (en) 2020-01-02
CN110494434A (zh) 2019-11-22
WO2018166993A3 (en) 2019-02-07
US11649241B2 (en) 2023-05-16
EP3596072B1 (en) 2022-06-22
US20210179626A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
CN108368116B (zh) Janus激酶抑制剂、其组合物及用途
CN110678467B (zh) 治疗化合物和组合物及其使用方法
US20200352951A1 (en) Therapeutic compounds and compositions, and methods of use thereof
US11649241B2 (en) Pyrazolochlorophenyl compounds, compositions and methods of use thereof
CN114026096B (zh) 四唑取代的吡唑并嘧啶类jak激酶抑制剂及其用途
US20230206644A1 (en) Pyrazolopyrimidine compounds as jak inhibitors
US20230242530A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
CN114008050B (zh) Jak激酶的吡唑并嘧啶芳基醚抑制剂及其用途
CN114008051B (zh) Jak激酶的吡唑并嘧啶砜抑制剂及其用途
HK40017827A (en) Pyrazolochlorophenyl compounds, compositions and methods of use thereof
HK40093207A (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a] pyridinyl compounds, compositions and methods of use thereof
HK40029259A (en) Pyrazolopyrimidine compounds as jak inhibitors
HK40009645B (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
HK40009645A (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
HK40019825A (en) Therapeutic compounds and compositions, and methods of use thereof
HK40019824A (en) Therapeutic compounds and compositions, and methods of use thereof
HK1258764B (en) Janus kinases inhibitors, compositions thereof and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40017827

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220524

CF01 Termination of patent right due to non-payment of annual fee